Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the ...

The new drug was approved by the UK medicines regulator on 14th February and is a successor to Sobi's long-established haemophilia A therapy Eloctate (efmoroctocog alfa), also sold by partner ...